Search research articles
Contact Us
Filters
Showing results (21-30 of 25) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 25 results.
The Journal of Rheumatology
|
May 1, 2025
Clinically Inactive Disease and Remission in Patients with Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post-Hoc Analysis of a Phase III Trial
Alessandro Consolaro, Nicolino Ruperto, Daniel J Lovell, et al.
Rheumatology and Therapy
|
December 16, 2022
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
Kevin L Winthrop, Arne Yndestad, Dan Henrohn, et al.
Annals of the Rheumatic Diseases
|
September 28, 2016
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
Daniel J Wallace, Vibeke Strand, Joan T Merrill, et al.
Annals of the Rheumatic Diseases
|
May 1, 2026
Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis
Hermine I Brunner, Mittermayer Santiago, Beth Gottlieb, et al.
ACR Open Rheumatology
|
October 8, 2025
Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial
Nicolino Ruperto, Daniel J Lovell, Olga Synoverska, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 25) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 25 results.
The Journal of Rheumatology
|
May 1, 2025
Clinically Inactive Disease and Remission in Patients with Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post-Hoc Analysis of a Phase III Trial
Alessandro Consolaro, Nicolino Ruperto, Daniel J Lovell, et al.
Rheumatology and Therapy
|
December 16, 2022
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
Kevin L Winthrop, Arne Yndestad, Dan Henrohn, et al.
Annals of the Rheumatic Diseases
|
September 28, 2016
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
Daniel J Wallace, Vibeke Strand, Joan T Merrill, et al.
Annals of the Rheumatic Diseases
|
May 1, 2026
Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis
Hermine I Brunner, Mittermayer Santiago, Beth Gottlieb, et al.
ACR Open Rheumatology
|
October 8, 2025
Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial
Nicolino Ruperto, Daniel J Lovell, Olga Synoverska, et al.
Page
of 3